Helix BioPharma Corp.

OTC: HBPCF · Healthcare · Biotechnology

Canadian filerHQ Toronto, ONReports USD

#1143 of 1,394 Healthcare companies by revenue

EA Score

——

FH 59DQ —GM —SS 52

v0.1 · 35/100 weight · pillars only

↑ balance-sheet leverage, Altman-Z · ↓ Piotroski F, workforce scale

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$3.6M

Employees

Market cap

$130.6M

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$00 CAD2025

Net income-$3.6M-5.0M CAD2025

Operating income-$3.6M-5.0M CAD2025

Total assets$13.5M18.7M CAD2025

Liabilities$2.3M3.2M CAD2025

Equity$11.2M15.5M CAD2025

Revenue trend

FY2018 – FY2025 · USD

FY18

FY19

FY20

FY21

FY22

FY23

FY24

FY25

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Helix BioPharma Corp. booked $0 in FY2025 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

MaxCyte, Inc.48D Tenaya Therapeutics, Inc.——Polaryx Therapeutics, Inc. Common Stock——The Joint Corp.75B+

Key facts

CEOThomas Mehrling

SectorHealthcare

IndustryBiotechnology

HeadquartersToronto, ON

ExchangeOTC: HBPCF

Employees7

IPO date2009-11-27

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.